Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial

被引：13
|
作者：
Shah, Nina
Delforge, Michel
San-Miguel, Jesus F.
Bertin, Kaitlyn B.
Tahir, Muna J.
Lewis, Hannah B.
Wang, Julie
Braverman, Julia
Campbell, Timothy B.
Dhanda, Devender
Munshi, Nikhil C.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136665
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
    Berdeja, Jesus G.
    Raje, Noopur S.
    Siegel, David S.
    Lin, Yi
    Anderson, Larry D., Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Einsele, Hermann
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy B.
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [22] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Minakata, Daisuke
    Ishida, Tadao
    Ando, Kiyoshi
    Suzuki, Rikio
    Tanaka, Junji
    Hagiwara, Shotaro
    Ananthakrishnan, Revathi
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Kanda, Yoshinobu
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) : 729 - 737
  • [23] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Daisuke Minakata
    Tadao Ishida
    Kiyoshi Ando
    Rikio Suzuki
    Junji Tanaka
    Shotaro Hagiwara
    Revathi Ananthakrishnan
    Shigeki Kuwayama
    Mitsufumi Nishio
    Yoshinobu Kanda
    Kenshi Suzuki
    International Journal of Hematology, 2023, 117 : 729 - 737
  • [24] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
    Raje, Noopur S.
    Siegel, David S.
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil C.
    Moreau, Philippe
    Goldschmidt, Hartmut
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy B.
    San-Miguel, Jesus F.
    Reece, Donna E.
    BLOOD, 2020, 136
  • [25] Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study
    Rodriguez-Otero, Paula
    San-Miguel, Jesus F.
    Anderson, Larry D., Jr.
    Lonial, Sagar
    Truppel-Hartmann, Anna
    Sanford, Jill
    Rowe, Everton
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD, 2021, 138
  • [26] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
    Weisel, K.
    Manier, S.
    Kansagra, A.
    Anderson, Jr L. D.
    Berdeja, J.
    Jagannath, S.
    Lin, Y.
    Lonial, S.
    Shah, N.
    Raje, N.
    Siegel, D.
    Oriol, A.
    Truppel-Hartmann, A.
    Rowe, E.
    Patel, P.
    Agarwal, A.
    Campbell, T. B.
    Rodriguez-Otero, P.
    Munshi, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180
  • [27] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
    Einsele, Hermann
    Berdeja, Jesus
    Raje, Noopur
    Siegel, David
    Lin, Yi
    Anderson, Larry, Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy
    Jagannath, Sundar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
  • [28] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
    Einsele, H.
    Berdeja, J.
    Raje, N. S.
    Siegel, D. S.
    Lin, Y.
    Anderson, L. D., Jr.
    Rodriguez-Otero, P.
    Manier, S.
    Cavo, M.
    Truppel-Hartmann, A.
    Rowe, E.
    Sanford, J.
    Wang, J.
    Campbell, T. B.
    Jagannath, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
  • [29] Idecabtagene vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study
    Goldschmidt, Hartmut
    Raje, Noopur
    Siegel, David
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil
    Moreau, Philippe
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy
    San-Miguel, Jesus
    Reece, Donna
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 50 - 50
  • [30] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Shah, N.
    Munshi, N.
    Berdeja, J.
    Jagannath, S.
    Finney, O.
    Martin, N.
    Agarwal, A.
    Rowe, E.
    Campbell, T. B.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
12345